title: Antioxidant effects of a single dose of acetylsalicylic acid and salicylic acid in rat brain slices subjected to oxygen-glucose deprivation in relation with its antiplatelet effect.
abstract: The aim of the present study was to analyze the relative participation of the antiplatelet and the antioxidant effects of acetylsalicylic acid (ASA) and salicylic acid (SA) after a single dose (1 or 10 mg/kg i.p.) in an in vitro model of anoxia in slices of rat brain. After 20 min of drug administration, blood and brain were obtained (n=6 rats per group). We measured: lipid peroxidation, glutathione levels and lactate dehydrogenase efflux (LDH), ASA and SA concentrations and platelet aggregation in whole blood. An increase in lipid peroxidation (80%) and in LDH efflux (520%) and a decrease in glutathione levels (35%) were observed after 120 min anoxia in saline-treated rats. SA reduced this oxidative stress and LDH efflux, but it did not modify platelet aggregation. ASA strongly inhibited platelet aggregation but exerted a poor antioxidant effect. ASA was not detectable in brain tissue. We conclude that repeated doses of ASA are necessary to obtain a tissular antioxidant effect, probably when liver generates enough SA.
authors.affiliation: Department of Pharmacology and Therapeutics, School of Medicine, University of Malaga, 29071 Malaga, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Guerrero
authors.forename: J A
authors.initials: JA
authors.lastname: González-Correa
authors.forename: M M
authors.initials: MM
authors.lastname: Arrebola
authors.forename: J
authors.initials: J
authors.lastname: Muñoz-Marín
authors.forename: F
authors.initials: F
authors.lastname: Sánchez de la Cuesta
authors.forename: J P
authors.initials: JP
authors.lastname: de la Cruz
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D001241:Aspirin / Q000493:pharmacokinetics*; D015687:Cell Hypoxia / Q000187:drug effects / Q000502:physiology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005947:Glucose / Q000378:metabolism; D005978:Glutathione / Q000187:drug effects / Q000378:metabolism; D020925:Hypoxia-Ischemia, Brain / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D066298:In Vitro Techniques; D007770:L-Lactate Dehydrogenase / Q000187:drug effects / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects / Q000502:physiology; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects* / Q000502:physiology; D010974:Platelet Aggregation / Q000187:drug effects / Q000502:physiology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D020156:Salicylic Acid / Q000493:pharmacokinetics*
chemical_list: D000975:Antioxidants; D004338:Drug Combinations; D010975:Platelet Aggregation Inhibitors; D007770:L-Lactate Dehydrogenase; D005978:Glutathione; D005947:Glucose; D020156:Salicylic Acid; D001241:Aspirin